Navigation Links
D-Pharm Secures Funding From Israel's Chief Scientist's Office

REHOVOT, Israel, April 7 /PRNewswire/ -- D-Pharm announced today that it received notice from Israel's Chief Scientist's Office (CSO) of its commitment to match expenditures on four of D-Pharm's R&D programs with a total grant of up to NIS 11 million (over $3 million).

Alex Kozak, PhD, CEO and President of D-Pharm, said "We are grateful to the CSO for this vote of confidence and its firm support over the years, from the time of the company's inception as a technological incubator. The CSO's backing has helped us to build a robust pipeline with two advanced clinical stage products in stroke (DP-b99) and epilepsy and migraine (DP-VPA) followed by an exciting range of preclinical developments in Alzheimer's disease, cancer and psoriasis".

D-Pharm's drug-development programs emerged from the company's unique platform technology of lipid-like medicine. The CSO grant supports four major company developments: GMP production of DP-b99 in-house, IND preparations and initiation of a pivotal Phase III trial in stroke patients; a Phase II migraine study of DP-VPA in Israeli medical centers; and two preclinical programs, DP-460 for Alzheimer's disease and LipidoMimetix for cancer.

The Chief Scientist's Office has supported D-Pharm since its establishment, providing grants of about $18 million, excluding this latest announcement.

About D-Pharm Ltd.

D-Pharm ( is clinical stage biopharmaceutical company pioneering the development of lipid-like therapeutics and has generated a rich pipeline of patent protected proprietary products. D-Pharm's pipeline includes advanced clinical stage products DP-b99 for treatment of acute ischemic stroke patients and DP-VPA, a novel drug for treatment of epilepsy, bipolar disorder and prophylaxis of migraine. D-Pharm recently received Israeli health ministry approval to commence a Phase II study of DP-VPA in migraine patients. DP-460 is in preclinical development intended as an oral, disease-modifying therapy for Alzheimer's disease. Other mimics of bioactive lipids, LipidoMimetix, are at an earlier developmental stage, for cancer. D-Pharm recently completed a $5 million rights issue to ensure timely commencement of the pivotal Phase III study of DP-b99, in acute stroke patients, as planned.

For further information please contact:

Tami Horovitz, PhD.

Tel: +972-8-9385100

Fax: +972-8-9300795


SOURCE D-Pharm Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. D-Pharm Completes Pre-IND Meeting With the FDA for Treatment of Acute Stroke With DP-b99
2. Aerovance Secures $20 Million in Debt Financing
3. Amarin Secures Global Intellectual Property Rights for Lipid Programs
4. Ranier Technology Secures GBP8m Funding for its Cadisc Replacement Spinal Discs
5. Halogen Announces Record Year - Company Solidifies Leadership Position, Secures Strategic Wins Over Competition
6. Taligen Therapeutics Secures Series B Financing
7. Neptune Technologies & Bioressources Inc. Secures Access to Nationwide Consumer Mass Market in the United States
8. Dendreon Secures $130 Million Committed Equity Financing Facility
9. Apollo Endosurgery, Inc. Secures $11.5 Million in Series A Financing.
10. Altheus Therapeutics Secures $3.6 Million in Venture Capital
11. Weil Gotshal Wins Major Victory for Applera; Secures Summary Judgment Invalidating Three Patents
Post Your Comments:
(Date:11/25/2015)... 2015 The Global Genomics ... professional and in-depth study on the current state ... ) , The report ... definitions, classifications, applications and industry chain structure. The ... markets including development trends, competitive landscape analysis, and ...
(Date:11/24/2015)... , Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: ... in New York on Wednesday, December 2 ... Torley , president and CEO, will provide a corporate overview. ... York at 1:00 p.m. ET/10:00 a.m. PT . ... relations, will provide a corporate overview. --> th ...
(Date:11/24/2015)... -- Clintrax Global, Inc., a worldwide provider of clinical research services headquartered ... the company has set a new quarterly earnings record in Q3 ... posted for Q3 of 2014 to Q3 of 2015.   ... , with the establishment of an Asia-Pacific ... United Kingdom and Mexico , with ...
(Date:11/24/2015)... New York , November 24, 2015 ... to a recent market research report released by Transparency ... projected to expand at a CAGR of 17.5% during ... "Non-invasive Prenatal Testing Market - Global Industry Analysis, Size, ... estimates the global non-invasive prenatal testing market to reach ...
Breaking Biology Technology:
(Date:11/4/2015)... November 4, 2015 --> ... report published by Transparency Market Research "Home Security Solutions Market ... Forecast 2015 - 2022", the global home security solutions market is ... by 2022. The market is estimated to expand at ... 2015 to 2022. Rising security needs among customers at ...
(Date:10/29/2015)... , Oct. 29, 2015   MedNet Solutions , ... entire spectrum of clinical research, is pleased to announce ... Tech Association (MHTA) as one of only three finalists ... "Software – Small and Growing" category. The Tekne Awards honor ... have shown superior technology innovation and leadership. ...
(Date:10/29/2015)... , Oct. 29, 2015 Daon, a ... that it has released a new version of its ... in North America have already ... v4.0 also includes a FIDO UAF certified server ... already preparing to activate FIDO features. These customers include ...
Breaking Biology News(10 mins):